EUCTR2008-008724-32-DE进行中（未招募）不适用
A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and older
Sanofi Pasteur MSD S.N.C.0 个研究点目标入组 456 人开始时间: 2009年4月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 456
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects have to meet all the following criteria to be eligible for inclusion:
- •1. Healthy adults aged =18 years,
- •2. Last booster with a T-containing vaccine received 5 to 10 years prior to the administration of the study vaccine (documented by written evidence),
- •3. Negative urine pregnancy test for female subjects of child-bearing potential. A female subject who is of reproductive potential must agree to remain abstinent or use (or have her partner use) acceptable methods of birth control during the study period,
- •4. Subject affiliated to a health social security system (for France only),
- •5. Subject having signed the informed consent form prior to participation in the study,
- •6. Subject able to attend all scheduled visits and to comply with all study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting at least one of the following criteria will be ineligible for inclusion:
- •1. Acute severe illness or fever (=38.0°C) within the last 3 days,
- •2. Hypersensitivity or known allergy to one of the components of one of the study vaccines (including formaldehyde, streptomycin, neomycin, polymyxin B, or glutaraldehyde),
- •3. Anaphylactic or other allergic reactions to a previous dose of a vaccine containing diphtheria or tetanus toxoids or poliomyelitis viruses or pertussis (acellular or whole cell),
- •4. Guillain Barré syndrome or neuropathy of brachial plexus following a previous vaccination with a tetanus toxoid containing vaccine,
- •5. Known encephalopathy after receipt of a pertussis vaccine or neurological disorders after an injection with the same antigens,
- •6. Progressive or unstable neurological disorder, uncontrolled seizures or progressive
- •encephalopathy not stabilized,
- •7. Known malignant disease;
- •Note: Subjects with prostate or breast cancer who are not on chemotherapeutic drugs (other than hormone blocking drugs), subjects with skin cancer who are not receiving radiation therapy or chemotherapy and subjects with a history of other malignancies who have been disease-free for at least 5 years will be eligible for enrolment.
- •8. Immunosuppressive therapy:
- •- High dose (= 20 mg/day prednisone equivalent) systemic (= 14 days) corticosteroid
- •treatment daily or on alternate day within the last 28 days (inhaled corticosteroids
- •- Chemotherapeutic agents used to treat cancer or other conditions,
- •- Treatments associated with organ or bone marrow transplantation.
- •9. Immune dysfunction caused by a medical condition, or any other cause (e.g. congenital immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma or generalized malignancy),
- •10. Known severe thrombocytopenia or coagulation disorder contraindicating an intramuscular injection,
- •11. Administration of blood products including immunoglobulins within the last 90 days or planned before Visit 3,
- •12. Recent administration of a live vaccine (=28 days) or an inactivated vaccine (=14 days) or vaccination planned before Visit 3,
- •13. For female subjects, pregnancy (positive pregnancy test before first blood sample) or breast-feeding through Visit 3,
- •14. Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalised without his/her consent,
- •15. Planned participation in another clinical study during the present study period,
- •16. Volunteer having been paid more than 4 500€ to take part in biomedical research during the previous 12 months (for France only).
研究者
相似试验
进行中（未招募）
1 期
A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and olderEUCTR2008-008724-32-FRSanofi Pasteur MSD S.N.C.
已完成
不适用
A phase III clinical trial for the two months safety and efficacy evaluation of Ostem™ (autologous cultured osteoblasts) in patients with fractureong bone fractureInjury, Occupational Diseases, PoisoningFractureISRCTN10637905Individual sponsor (South Korea)77
已完成
3 期
A multicentric, randomized, comparative clinical trial of Armodafinil versus Modafinil in patients with excessive sleepiness associated with shift work sleep disorder (SWSD).CTRI/2009/091/000617Emcure Pharmaceuticals Ltd Pune.
已完成
3 期
A Randomised, Comparative, Multicentre Clinical Trial of the Immunogenicity and Safety of Tdap-IPV Vaccine and a Tetanus Monovalent Vaccine in Healthy Adults 18 Years of Age and OlderA35Other tetanustetanusDRKS00000180Sanofi Pasteur MSD456
进行中（未招募）
不适用
se of the corifolitropina alfa in oocyte donorsThe study is proposed to determine the level of compliance and pharmacoeconomic impact of three protocols for controlled ovarian stimulation in women participating in oocyte donation programEUCTR2014-001743-20-ESIVI Madrid